Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneDx HoldingsWGS +3.30%65 Net Cash per Share is $-3.51 as of Jun. 2026. GuruFocus rates WGS with a GF Score™ of 65/100 and a GF Value™ of $73.77 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 59 Medical Diagnostics & Research companies, GeneDx Holdings ranks worse than 1694913.56% on this metric.
The historical rank and industry rank for GeneDx Holdings's Net Cash per Share or its related term are showing as below:
During the past 7 years, the highest Price-to-Net-Cash Ratio of GeneDx Holdings was 7.32. The lowest was 4.61. And the median was 5.93.
WGS's Price-to-Net-Cash is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 9.24 * Ranked among companies with meaningful Price-to-Net-Cash only.
GeneDx Holdings (NAS:WGS) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
GeneDx Holdings Net Cash per Share Related Terms
GeneDx Holdings Net Cash per Share Historical Data
* Premium members only.
The historical data trend for GeneDx Holdings's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WGS vs NEO, CDNA, PSNL: Net Cash per Share Comparison
For the Diagnostics & Research subindustry, GeneDx Holdings's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneDx Holdings Price-to-Net-Cash vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where GeneDx Holdings's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
GeneDx Holdings's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneDx Holdings (WGS) has a Net Cash per Share of $-3.51 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on GeneDx Holdings and its competitors. According to the industry distribution chart, GeneDx Holdings ranks #999999 out of 59 companies in the Medical Diagnostics & Research industry.
Is GeneDx Holdings' Net Cash per Share too high?
GeneDx Holdings' current Net Cash per Share is $-3.51. Based on the distribution chart, GeneDx Holdings ranks #999999 out of 59 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Net Cash per Share compare to NEO and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, GeneDx Holdings ranks #999999 out of 59 companies for Net Cash per Share. This places GeneDx Holdings in the lower half of its industry. The industry median Net Cash per Share is 9.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Diagnostics & Research company?
The median Net Cash per Share among Medical Diagnostics & Research companies is 9.24, based on 59 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on GeneDx Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Net Cash per Share is 9.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneDx Holdings's current Net Cash per Share is $-3.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $90.32 — trading 22.4% above its estimated fair value. The current Net Cash per Share is $-3.51. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Net Cash per Share is $-3.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneDx Holdings (WGS) Overvalued in 2026?
Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued.
The current stock price of $90.32 is trading 22.4% above its estimated GF Value™ of $73.77.
GuruFocus considers GeneDx Holdings to be Modestly Overvalued.
Key valuation signals for WGS:
Net Cash per Share: $-3.51
GF Value™: $73.77 vs. price of $90.32 (22.4% above fair value)
No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score
Get the complete analysis for WGS
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WGS has been successfully added to your 
